Selinexor Plus Ruxolitinib Patients with Treatment-Naïve Myelofibrosis

Haris Ali and collaborating researchers evaluated the combination of selinexor and ruxolitinib in patients with treatment-naïve myelofibrosis. In their data, presented at the 2022 American Society of Clinical Oncology Annual Meeting, the researchers reported that the combination was well-tolerated with manageable side effects, and no dose limited toxicities were reported.

At the time of the presentation, the study had enrolled 10 patients to two selinexor dosage groups, 40 mg (n = 3) and 60 mg (n = 7). Ruxolitinib was started at 20 mg in eight patients, 15 mg in one patient, and 10 mg in one patient. No unmanageable toxicities were seen in either dosage group, though one patient interrupted treatment and later discontinued due to new onset atrial fibrillation and pulmonary hypertension after five months of intervention treatment. The most common treatment-emergent adverse event was low-grade nausea in 30% of patients.

All patients maintained hemoglobin levels and achieved improvements in white blood cell count. Finally, among the first five evaluable patients, four experienced a ≥35% reduction in spleen volume at week 12.

Ultimately, the authors presented their preliminary data in support of the use of combined selinexor and ruxolitinib in patients with myelofibrosis.

SOURCEASCO